Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhodiola Rosea in Coronary Microvascular Disease
NCT04218916Phase 3Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Vitano in coronary microvascular disease (CMD), sponsored by Qilu Hospital of Shandong University. Status: unknown.
02
Drugs
Vitano
03
Conditions
coronary microvascular disease (CMD)
Beyond the preview
Go deeper on NCT04218916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218916.